This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
uPA/PAI system, cathepsin B and hepatocellular carcinoma
Qing-Qing Shi, Ji-Qiao Xiang, Lan Chen, Ling-Ling Zhan, Xiao-Ping Lv
Qing-Qing Shi, Ji-Qiao Xiang, Lan Chen, Xiao-Ping Lv, Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Ling-Ling Zhan, Department of Clinical Experimental Medicine, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Supported by: The Natural Science Foundation of Guangxi, No. 2012GXNSFAA053143; the Scientific Research and Technology Development Program of Guangxi, No. 1355005-3-2.
Correspondence to: Xiao-Ping Lv, Professor, Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. lxxp58@hotmail.com
Received: June 16, 2014 Revised: July 7, 2014 Accepted: July 28, 2014 Published online: September 18, 2014
Urokinase-type plasminogen activator and plasminogen activator inhibitor (uPA/PAI) are a pair of proteolytic enzyme activator/activator inhibitor. Cathepsin B is a lysosomal cysteine protease. It has been proved that cathepsin B can activate uPA. uPA/PAI and cathepsin B are closely related to the invasion, migration and tumor angiogenesis of malignant neoplasms. The uPA/PAI system and cathepsin B play an important role in the occurrence and development of liver cancer.
Zhou Y, Lǚ X, Li S, Zhan L. Correlation between the overexpression of urokinase receptor isoform uPAR (D1D2) and hepatic cell malignant transformation.Mol Med Rep. 2014;9:1689-1696.
[PubMed] [DOI]
Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ. Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B.J Biol Chem. 2002;277:14829-14837.
[PubMed] [DOI]
Takada Y. Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).J Biomed Biotechnol. 2012;2012:136302.
[PubMed] [DOI]
Tarui T, Akakura N, Majumdar M, Andronicos N, Takagi J, Mazar AP, Bdeir K, Kuo A, Yarovoi SV, Cines DB. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.Thromb Haemost. 2006;95:524-534.
[PubMed] [DOI]
Reuning U, Bang NU. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens.Arterioscler Thromb. 1992;12:1161-1170.
[PubMed] [DOI]
Jo M, Thomas KS, Marozkina N, Amin TJ, Silva CM, Parsons SJ, Gonias SL. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator.J Biol Chem. 2005;280:17449-17457.
[PubMed] [DOI]
Dutta S, Bandyopadhyay C, Bottero V, Veettil MV, Wilson L, Pins MR, Johnson KE, Warshall C, Chandran B. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.Mol Oncol. 2014;8:483-507.
[PubMed] [DOI]
Margheri F, Luciani C, Taddei ML, Giannoni E, Laurenzana A, Biagioni A, Chillà A, Chiarugi P, Fibbi G, Del Rosso M. The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.Oncotarget. 2014;5:1538-1553.
[PubMed] [DOI]
Sasaki T, Nishi H, Nagata C, Nagai T, Nagao T, Terauchi F, Isaka K. A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.Int J Clin Oncol. 2014; Jan 30. [Epub ahead of print].
[PubMed] [DOI]
Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).PLoS One. 2014;9:e85349.
[PubMed] [DOI]
Gopal GJ, Kumar A, Pal J, Mukhopadhyay G. Molecular characterization and polyclonal antibody generation against core component CagX protein of Helicobacter pylori type IV secretion system.Bioengineered. 2014;5:107-113.
[PubMed] [DOI]
Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome.Anticancer Res. 2014;34:1153-1161.
[PubMed] [DOI]
Schroder WA, Major LD, Le TT, Gardner J, Sweet MJ, Janciauskiene S, Suhrbier A. Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.Cancer Med. 2014;3:500-513.
[PubMed] [DOI]
Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.Mol Cancer Ther. 2013;12:2697-2708.
[PubMed] [DOI]
Sevenich L, Werner F, Gajda M, Schurigt U, Sieber C, Müller S, Follo M, Peters C, Reinheckel T. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.Oncogene. 2011;30:54-64.
[PubMed] [DOI]
Gong F, Peng X, Luo C, Shen G, Zhao C, Zou L, Li L, Sang Y, Zhao Y, Zhao X. Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma.Mol Cancer. 2013;12:125.
[PubMed] [DOI]
Chan AT, Baba Y, Shima K, Nosho K, Chung DC, Hung KE, Mahmood U, Madden K, Poss K, Ranieri A. Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia.Cancer Epidemiol Biomarkers Prev. 2010;19:2777-2785.
[PubMed] [DOI]
Bao W, Fan Q, Luo X, Cheng WW, Wang YD, Li ZN, Chen XL, Wu D. Silencing of Cathepsin B suppresses the proliferation and invasion of endometrial cancer.Oncol Rep. 2013;30:723-730.
[PubMed] [DOI]
Tummalapalli P, Spomar D, Gondi CS, Olivero WC, Gujrati M, Dinh DH, Rao JS. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.Int J Oncol. 2007;31:1039-1050.
[PubMed] [DOI]
Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.Cancer. 1996;77:1079-1088.
[PubMed] [DOI]
Alkim H, Ayaz S, Sasmaz N, Oguz P, Sahin B. Hemostatic abnormalities in cirrhosis and tumor-related portal vein thrombosis.Clin Appl Thromb Hemost. 2012;18:409-415.
[PubMed] [DOI]
Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX, Xing BC. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.World J Surg. 2013;37:608-613.
[PubMed] [DOI]
Niewczas M, Paczek L, Krawczyk M, Pawlak J, Bartłomiejczyk I, Górnicka B. [Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma].Pol Arch Med Wewn. 2002;108:653-662.
[PubMed] [DOI]
Chen WN, Chen JY, Jiao BY, Lin WS, Wu YL, Liu LL, Lin X. Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.J Virol. 2012;86:13533-13541.
[PubMed] [DOI]
Nishikawa H, Ozaki Y, Nakanishi T, Blomgren K, Tada T, Arakawa A, Suzumori K. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer.Gynecol Oncol. 2004;92:881-886.
[PubMed] [DOI]
Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K. Cathepsin B inhibition limits bone metastasis in breast cancer.Cancer Res. 2012;72:1199-1209.
[PubMed] [DOI]
Matarrese P, Ascione B, Ciarlo L, Vona R, Leonetti C, Scarsella M, Mileo AM, Catricalà C, Paggi MG, Malorni W. Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study.Mol Cancer. 2010;9:207.
[PubMed] [DOI]
Victor BC, Anbalagan A, Mohamed MM, Sloane BF, Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion.Breast Cancer Res. 2011;13:R115.
[PubMed] [DOI]
Zhang S, Ma Y, Jiang J, Dai Z, Gao X, Yin X, Xi W, Min W. Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells.Oncol Lett. 2014;7:1375-1380.
[PubMed] [DOI]
Gorantla B, Asuthkar S, Rao JS, Patel J, Gondi CS. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells.Mol Cancer Res. 2011;9:377-389.
[PubMed] [DOI]
Veeravalli KK, Chetty C, Ponnala S, Gondi CS, Lakka SS, Fassett D, Klopfenstein JD, Dinh DH, Gujrati M, Rao JS. MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice.PLoS One. 2010;5:e11583.
[PubMed] [DOI]